Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

ed to enter into another alliance with Ipsen. This collaboration is an opportunity to grow our pipeline in oncology, our area of expertise. We believe that Debio 0931 may have applications in the treatment of various types of cancer which will increase the quality of life of many cancer patients."

About the partnership

The collaboration between Ipsen and Debiopharm started in 1983 with regards to LHRH analogues, in particular for the triptorelin analogue Decapeptyl(R) (also known as Pamoreline(R) and Diphereline(R)). In October 2007, their partnership was extended to grant Ipsen access to future sustained-release formulations of Decapeptyl(R) developed by Debiopharm, among which a 6-month sustained release formulation that was filed in Europe in September 2008, for the treatment of locally advanced or metastatic prostate cancer. Decapeptyl(R) 1 and 3-month formulations are currently commercialised in more than 60 countries worldwide, including 25 in Europe and they have generated almost EUR 248million in sales in 2008.

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partne
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the global pharmaceutical, biotechnology, ... Investigational New Drug (IND) application for WuXi MedImmune,s ... been accepted for review by the China Food ... September 2012, MedImmune, the global biologics research and ...
(Date:3/26/2015)... WARREN, N.J., March 26, 2015  Roka Bioscience, ... company focused on providing advanced testing solutions for ... financial results for the three months and full ... Quarter 2014 Financial Results:Revenue for the quarter ended ... $689,000 for the fourth quarter of 2013 and ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Market ... formed a strategic alliance with Designing Gig LLC to ... clients. , “Forging this alliance with Designing ... Now we can extend a comprehensive, end-to-end, digital solution ... strategy, and execution,” said Chuck Miller, president of The ...
(Date:3/26/2015)... Corporation (NASDAQ: NEOG ) announced today that its ... which ended Feb. 28, increased 13% to $7,454,000, when ... in the current quarter were $0.20, compared to $0.18 ... over prior year to $24,142,000, or $0.65 per share, ... same period a year ago. Revenues for ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... LLC ( http://www.trimarkpublications.com ), a global leader in the ... newly published Regenerative Medicine Markets report that ... $3 billion in 2010 and is expected to reach ... to treat injuries and diseases with specially-grown tissues by ...
... YOKOHAMA, Japan, September 1, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in ...
Cached Biology Technology:Regenerative Medicine Market Expected to Reach $4.5 Billion by 2014 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 3ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 4ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 5ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 6Medisafe 1 Technologies Announces 1-5 Stock Dividend 2Medisafe 1 Technologies Announces 1-5 Stock Dividend 3Medisafe 1 Technologies Announces 1-5 Stock Dividend 4Medisafe 1 Technologies Announces 1-5 Stock Dividend 5Medisafe 1 Technologies Announces 1-5 Stock Dividend 6
(Date:3/10/2015)... -- Continuing its 167-year history of offering the Best, the ... Eye Scanning Password Authenticator , a device that confirms ... or sensitive data. Employing the same biometric ... device has a small camera that scans and saves ... them into an encrypted ID that cannot be forged ...
(Date:3/10/2015)... March 10, 2015  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the ... smart wallet has been named the "Number One ... Rethink Modern ( http://www.rethinkmodern.com/ ) is ... your home and lifestyle that have a unique function ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... cancer,patients have an abnormality in a specific cell ... pathway may be,especially effective for treating the disease, ... D. Anderson Cancer Center.", , A clearer picture ... 3 kinase (PI3K),pathway to breast cancer development, says ...
... large, multisite trial designed to examine the safety ... to prevent HIV infection has opened to volunteer ... of Allergy and Infectious Diseases (NIAID), part of ... among various research institutions in Africa and the ...
... brain-clogging deposits that cause such disorders as Alzheimer's ... out how to capture and "micromanipulate" the single ... aim is to understand the detailed assembly process ... basic understanding, they said, could lead to approaches ...
Cached Biology News: MetaChip provides quick, efficient toxicity screening of potential drugs 2Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimer's, Parkinson's Disease 2
... and easy to use Ascent ... all members of the Ascent ... a clear and easy-to-follow approach ... user-friendly and highly sophisticated data ...
... Lambda Protein Phosphatase ... Mn2+-dependent protein phosphatase with ... threonine and tyrosine residues. ... amino-acid product of the ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
Biology Products: